Related Experiment Video
Updated: Jun 26, 2025
04:06
Author Spotlight: Minimally Invasive Relief for Occipital Neuralgia at the Nuchal Line
Published on: September 13, 2024
1.9K
Orbital decompression surgery among Medicare beneficiaries in the post-teprotumumab era
Akash M Bhat1,2, Zachary M Soler1, Rodney J Schlosser1,3
1Division of Rhinology and Sinus Surgery, Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
International Forum of Allergy & Rhinology
|May 8, 2024
Abstract
Key Points:
Utilization of orbital decompressions (ODS) increased (CAGR: +3.2%) from 2000 to 2019. FDA approved teprotumumab in January 2020; ODS utilization decreased (CAGR: -14.9%) from 2019 to 2022. In 2022, total spending was substantially higher for teprotumumab ($325 million) than surgery ($580,000).
